GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS
This article was originally published in The Tan Sheet
GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS to FDA on Sept. 8. The submission includes five clinical studies and two guinea pig studies sponsored by Givaudan-Roure customers outside the U.S., as well as other data intended to support a Category I (safe and effective) listing of the broad- spectrum sunscreen. The data are intended to bolster the company's citizen petition seeking monograph status for Parsol 1789 (avobenzone).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC